ORIC Oric Pharmaceuticals Inc
Price (delayed)
$5.19
Market cap
$368.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.83
Enterprise value
$309.22M
ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist
Highlights
The EPS has increased by 7% year-on-year
Oric Pharmaceuticals's equity has decreased by 11% QoQ but it has increased by 8% YoY
ORIC's net income is down by 27% year-on-year and by 7% since the previous quarter
The quick ratio has declined by 20% since the previous quarter
Key stats
What are the main financial stats of ORIC
Market
Valuations
Earnings
Shares outstanding
71.03M
Market cap
$368.63M
Enterprise value
$309.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.9M
Net income
-$127.85M
EBIT
-$127.85M
EBITDA
-$126.74M
Free cash flow
-$113.85M
Per share
Balance sheet
Liquidity
EPS
-$1.83
EPS diluted
-$1.83
Free cash flow per share
-$1.63
Book value per share
$3.45
Revenue per share
$0
TBVPS
$3.93
Total assets
$274.14M
Total liabilities
$31.02M
Debt
$0
Equity
$243.12M
Working capital
$237.4M
Debt to equity
0
Current ratio
10.56
Quick ratio
10.3
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.7%
Return on equity
-44.5%
Return on invested capital
-53%
Return on capital employed
-51.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORIC stock price
How has the Oric Pharmaceuticals stock price performed over time
Intraday
0.39%
1 week
8.81%
1 month
-29.58%
1 year
-35.77%
YTD
-35.69%
QTD
-6.99%
Financial performance
How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.9M
Net income
-$127.85M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 29% year-on-year and by 6% since the previous quarter
ORIC's net income is down by 27% year-on-year and by 7% since the previous quarter
Growth
What is Oric Pharmaceuticals's growth rate over time
Valuation
What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 7% year-on-year
The stock's P/B is 34% less than its last 4 quarters average of 2.3 and 31% less than its 5-year quarterly average of 2.2
Oric Pharmaceuticals's equity has decreased by 11% QoQ but it has increased by 8% YoY
Efficiency
How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has decreased by 9% QoQ
The return on equity has declined by 4.7% since the previous quarter and by 4.2% year-on-year
The ROA has declined by 5% year-on-year and by 4.6% since the previous quarter
Dividends
What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORIC.
Financial health
How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 20% since the previous quarter
The company's current ratio fell by 20% QoQ
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has decreased by 11% QoQ but it has increased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.